Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RZLT
SELLRezolute, Inc. · Healthcare · United States · $480M · Avg Vol: $10M/d
COMPANY DESCRIPTION
Rezolute, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for rare metabolic diseases, with its lead candidate, RZ358, targeting congenital hyperinsulinism (CHI). The company addresses severe unmet medical needs where therapeutic options are limited, with its pipeline targeting orphan diseases that may benefit from expedited regulatory processes and market exclusivity. Rezolute is a biotechnology firm concentrating on developing specialized treatments for rare diseases to serve underserved patient populations.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — | — | 2.3M | — |
| EPS | — | -0.79 | -0.39 | -1.33 | -0.98 | — | -0.78 | -0.69 | -0.63 | — |
| Shares | — | 96.3M | 96.3M | 53.2M | 87.0M | -9.7% | 96.3M | — | — | — |
| Debt | 14.0M | 0.2M | 2.5M | 2.2M | 1.6M | -41.7% | 1.1M | — | — | — |
| Equity | — | 149.5M | 116.2M | 121.0M | 162.1M | 2.7% | — | — | — | — |
| Op CF | — | -39.6M | -44.5M | -57.4M | -69.1M | — | -73.5M | — | — | — |
| Inv CF | — | 0 | -101.5M | 48.7M | -14.5M | — | — | — | — | — |
| Fin CF | — | 149.0M | 11.6M | 63.0M | 107.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RZLT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RZLT | Rezolute, Inc.(you) | $480M | 23 | SELL |
| ASMB | Assembly Biosciences, Inc. | $506M | 23 | SELL |
| ZURA | Zura Bio Limited | $496M | 22 | SELL |
| ARTV | Artiva Biotherapeutics, Inc. | $487M | 26 | SELL |
| LRMR | Larimar Therapeutics, Inc. | $416M | 23 | SELL |
| BNTC | Benitec Biopharma Inc. | $394M | 24 | SELL |
| ARVN | Arvinas, Inc. | $518M | 20 | STRONG SELL |
| ENTA | Enanta Pharmaceuticals, Inc. | $372M | 23 | SELL |
| PRTC.L | PureTech Health plc | $421M | 26 | SELL |
| NVCT | Nuvectis Pharma, Inc. | $609M | 25 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%